advertisement
Science News
from research organizations

Metabolic effects of an oral blood cancer drug

Date:
November 12, 2019
Source:
The Mount Sinai Hospital / Mount Sinai School of Medicine
Summary:
A recent study found that an effective blood cancer treatment was associated with weight gain, obesity, and increased systolic blood pressure.
Share:
advertisement

FULL STORY

A popular cancer drug is associated with significant weight gain and increased systolic blood pressure, researchers from the Icahn School of Medicine at Mount Sinai report in a study published inScientific Reportsin November.

The drug, ruxolitinib, was the first and currently remains the most widely used FDA-approved mechanism-based therapy for myeloproliferative neoplasms (MPNs), blood cancers that include myelofibrosis and polycythemia vera. Ruxolitinib is a Janus kinases (JAK) 1/2 inhibitor, an enzyme-blocker that affects blood cell production.

As cancer therapies improve, and patients are living longer on them, understanding the long-term consequences of these targeted therapies on metabolic health is increasingly important.

"Weight gain with ruxolitinib has previously been reported in clinical trials, but our study provides real-world experience regarding the extent of that weight gain," said Emily J. Gallagher, MD, PhD, the study's lead author and Assistant Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at the Icahn School of Medicine at Mount Sinai, specializing in onco-endocrinology, the treatment of endocrine complications of oncology treatments. "We recommend that patients who go on this medication and do have an increase in weight get a full metabolic evaluation."

研究人员研究了69个或然数患者started on ruxolitinib from 2010 to 2017 at Mount Sinai. The patients' medical records had data on metabolic parameters up to one year prior to starting ruxolitinib and 72 weeks after starting the drug. They found that more than half of patients taking this medication gained more than 5 percent in body weight. The weight gain was also associated with an increase in systolic blood pressure and liver enzymes.

"In contrast to the perception of many health care providers, patients are not going from being underweight to being a normal weight. Instead, a significant number of patients are developing obesity. Based on these results, physicians should be aware of the potential effects, and counsel patients accordingly," said Dr. Gallagher.

This study is the first step in documenting the metabolic consequences of this drug. Further studies are needed to gain a greater understanding of the changes in hormones and metabolism in those receiving treatment for this condition.

advertisement

Story Source:

Materialsprovided byThe Mount Sinai Hospital / Mount Sinai School of Medicine.注意:内容可能被编辑风格d length.


Journal Reference:

  1. Manali Sapre, Douglas Tremblay, Eric Wilck, Annie James, Amanda Leiter, Alexander Coltoff, Anita G. Koshy, Marina Kremyanskaya, Ronald Hoffman, John O. Mascarenhas, Emily J. Gallagher.Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.Scientific Reports, 2019; 9 (1) DOI:10.1038/s41598-019-53056-x

Cite This Page:

The Mount Sinai Hospital / Mount Sinai School of Medicine. "Metabolic effects of an oral blood cancer drug." ScienceDaily. ScienceDaily, 12 November 2019. .
The Mount Sinai Hospital / Mount Sinai School of Medicine. (2019, November 12). Metabolic effects of an oral blood cancer drug.ScienceDaily. Retrieved July 1, 2023 from www.koonmotors.com/releases/2019/11/191112073610.htm
The Mount Sinai Hospital / Mount Sinai School of Medicine. "Metabolic effects of an oral blood cancer drug." ScienceDaily. www.koonmotors.com/releases/2019/11/191112073610.htm (accessed July 1, 2023).

Explore More
from ScienceDaily

RELATED STORIES

advertisement